Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed...

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers graft-versus-lymphoma effects for relapsed or refractory non-Hodgkin lymphoma (NHL).
• Therapy-related mortality (TRM) is a significant challenge in allo-HSCT for NHL.
• Reduced-intensity conditioning (RIC) regimens aim to mitigate TRM while preserving anti-lymphoma activity.

Purpose of the Study:

• To evaluate the efficacy and safety of a specific RIC regimen for allo-HSCT in patients with relapsed or refractory NHL.
• To assess overall survival (OS), disease-free survival (DFS), TRM, and relapse incidence.
• To analyze the impact of graft-versus-host disease (GVHD) on survival outcomes.

Main Methods:

• A cohort of 28 patients with relapsed or refractory NHL underwent allo-HSCT between 2007 and 2013.
• The RIC regimen consisted of fludarabine (FLU), melphalan (MEL), and total body irradiation (TBI).
• Peripheral blood stem cells were sourced from matched sibling or unrelated donors.

Main Results:

• Complete remission was achieved in 78.5% of patients post-allo-HSCT.
• Three-year OS and DFS were 62.4% and 59.2%, respectively.
• Three-year TRM was 14.9% and relapse incidence was 28.6%. Chronic GVHD correlated with favorable survival.

Conclusions:

• RIC-allo-HSCT using FLU + MEL + TBI is a viable treatment option for relapsed or refractory NHL.
• This regimen provides favorable survival outcomes with manageable TRM and relapse rates.
• Further research into optimizing RIC protocols and GVHD prophylaxis is warranted.